News

ModiQuest Research, a leading custom antibody generation and development company, will be attending the Protein engineering summit this May 1-5 in Boston.
Immunized animals are still a key source of antibodies generated within therapeutic campaigns to obtain high affinity antibody drug candidates. Therefore, humanization and de-risking of these antibodies is an important antibody engineering step in the development of therapeutic antibodies. However, humanization is still characterized by a high risk as affinity and specificity can be lost during the humanization process.
ModiQuest Research will present a full antibody engineering platform (ModiTuneTM) to obtain humanized antibodies with similar affinity and specificity as the original antibody.
Meet Debby Kruijsen (Head contract research) and Nienke Smits (Business development) at booth #209 or at our poster to discover our state of the art antibody generation and engineering platforms and to discuss your specific antibody projects.
If you have any questions, inquiries or if you would like to arrange a meeting during the event, please don’t hesitate to contact us. Mail to: nsmits@modiquestresearch.com or call us on +31 412 846 000 to fix a time to talk.
Hope to meet you at the PEGS Boston!

Debby Kruijsen and Nienke Smits

Dr. D. Kruijsen (dkruijsen@modiquestresearch.com)

We are pleased to announce that ModiQuest Research has acquired ’Crédit d’Impôt Recherche’ (CIR) accreditation from the French Ministry of Higher Education and Research. The French R&D tax credit initiative gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim significant tax reduction on costs generated in R&D activities outsourced to ModiQuest Research.

For over 10 years ModiQuest Research specializes in the generation of monoclonal antibodies against difficult target antigens for R&D, diagnostic and therapeutic applications. Using our proprietary ModiVaccTM (cell immunisation) ModiFuseTM (electrofusion hybridoma), ModiSelectTM (B-cell selection) and ModiPhageTM (phage display) technologies, we can generate monoclonal antibodies from various backgrounds such as mouse, rat, rabbit, chicken, llama and human against virtually any target. Besides lead antibody generation, we also provide antibody development and optimization (ModiTuneTM), such as affinity maturation, humanization and production (ModiXpressTM) in transient and stable mammalian cell systems. All services are offered on a fee-for-service basis.


ModiQuest Research will be attending the AET conference

ModiQuest Research, a leading custom antibody generation and development company, will be attending the Antibody Engineering and Therapeutics conference this December 11-15 in San Diego.

There is a substantial interest in high-quality, functional antibodies against membrane spanning proteins, especially those considered intractable targets. Generating antibodies against these targets is very challenging, and crucial for therapeutic and diagnostic antibody development. ModiQuest Research has developed novel tumor-specific antibodies with high therapeutic and diagnostic potential.

ModiQuest Research will present the generation and characterization of a panel of lead antibodies to a therapeutically relevant transmembrane protein by exploiting ModiQuest’s proprietary technology platform and subsequent high-throughput screening in less than a year.

Meet Dr. Jos Raats (CEO) at our poster to discover our state of the art antibody generation and technology platforms and to discuss your specific antibody projects.

If you have any questions, inquiries or if you would like to arrange a meeting during the event, please don’t hesitate to contact us. Mail to: nsmits@modiquestresearch.com or call us on +31 412 846 000 to fix a time to talk.

Hope to meet you at the AET San Diego!

Jos Raats

 

The inaugural Milner Therapeutics Symposium, From Basic Research to Drugs in Patients, will be held on 17 November 2016 at St. Catharine’s College, Cambridge.

The Milner Therapeutics Symposium is a one day event that will bring together world-leading scientists in cancer biology, neurobiology, immunology and regenerative medicine with top companies from the pharmaceutical and biotechnology sector

For further information: http://www.milner.cam.ac.uk/Symposium2016

Amongst other subjects this webinar will overview:

How ModiQuest Research maximized their chances of finding therapeutic leads by implementing the iQue Screener platform, speaker Andrea Gorlani, Ph.D., scientist.

For more information see: Webinar Intellicyt

 

shopping basket 0 items

Shopping Cart

0

Your shopping cart is empty:

please visit the shop